Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $125 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.